Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Arm shot may boost walking after stroke

NCT ID NCT04908423

Symptom relief Sponsor: Wake Forest University Health Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether injecting Xeomin® into the upper arm can improve walking and quality of life in adults who have weakness on one side after a stroke. Twenty participants will be measured before and 4-6 weeks after the injection using walking tests and a sensor. The goal is to see if treating arm spasticity has a ripple effect on mobility.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Xeomin® (incobotulinumtoxinA, a botulinum toxin type A)
What this could lead to
If it works, this could point toward a way to improve walking and daily function for stroke survivors with arm spasticity.
What could go wrong
This is a small pilot study with only 20 people, so results may not apply widely. The injection is in the arm, so any walking benefit is indirect and uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2021

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 79 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of hemiparesis and spasticity secondary to stroke with upper and lower limb spasticity and unilateral motor and/or sensory deficit * No prior surgery to the lower limb * Able to walk at least 10 meters without physical assistance from another person and without an assistive device * Toe- ground clearance during swing phase without assistive device or orthoses * No treatment with botulinum toxin within the past 4 months Exclusion Criteria: * Passive range of motion at either the ankle, knee, or elbow joint less than 30 degrees * Participants with uncorrected hearing impairment * Weight bearing restrictions due to concurrent orthopedic injuries that would make ambulating with or without an assistive device unsafe * Speech language expression deficit (e.g., aphasia) * Absence of proprioception upon neurologic examination * Presence of fixed contractures in the upper or lower extremities not correctable to neutral * Other confounding neurological diagnoses or active acute illness (cancer, Parkinson's disease, multiple sclerosis)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Carolinas Rehabilitation

    RECRUITING

    Charlotte, North Carolina, 28203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.